{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.22","upperLimit":"0.44","value":"0.32"},{"groupId":"OG001","lowerLimit":"0.17","upperLimit":"0.39","value":"0.27"},{"groupId":"OG002","lowerLimit":"0.26","upperLimit":"0.67","value":"0.46"},{"groupId":"OG003","lowerLimit":"0.05","upperLimit":"0.39","value":"0.17"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"75"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"}],"units":"Participants"}],"description":"Clinical response is defined as a complete response (CR), partial response (PR) or trilineage response (TR) graded according to the following criteria:\n\n1. World Health Organization classification of the acute leukemias and myelodysplastic syndrome (by Bennett)\n2. Myelodysplastic syndromes standardized response criteria: further definition (by Cheson et al.)\n3. Report of an international working group to standardize response criteria for myelodysplastic syndromes (by Cheson et al.)","dispersionType":"95% Confidence Interval","groups":[{"description":"Non-treatment-induced patients receive azacitidine (50 mg/m2) subcutaneously once daily on days 1-10 in a 28-day cycle.","id":"OG000","title":"Arm A (Azacitidine; Non-treatment-induced Cohort)"},{"description":"Non-treatment-induced patients receive azacitidine as in arm A and oral entinostat (4 mg/m2) on days 3 and 10 of each 28-day cycle.","id":"OG001","title":"Arm B (Azacitidine + Entinostat; Non-treatment-induced Cohort)"},{"description":"Treatment-induced patients receive azacitidine (50 mg/m2) subcutaneously once daily on days 1-10 in a 28-day cycle.","id":"OG002","title":"Arm A (Azacitidine; Treatment-induced Cohort)"},{"description":"Treatment-induced patients receive azacitidine as in arm A and oral entinostat (4 mg/m2) on days 3 and 10 of each 28-day cycle.","id":"OG003","title":"Arm B (Azacitidine + Entinostat; Treatment-induced Cohort)"}],"paramType":"NUMBER","populationDescription":"All treated patients are included in the analysis.","reportingStatus":"POSTED","timeFrame":"Assessed every 3 months if patient is < 2 years from study entry, every 6 months if patient is 2 - 5 years from study entry.","title":"Proportion of Patients With Clinical Response","type":"PRIMARY","unitOfMeasure":"Proportion of patients"}